← Back to Screener
Biogen Inc. Common Stock (BIIB)
Price$183.34
Favorite Metrics
Price vs S&P 500 (26W)19.82%
Price vs S&P 500 (4W)-8.30%
Market Capitalization$26.94B
P/E Ratio (Annual)20.84x
All Metrics
P/CF (Annual)12.22x
Book Value / Share (Quarterly)$124.45
P/TBV (Annual)2.84x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.93%
Cash Flow / Share (Quarterly)$13.76
Price vs S&P 500 (YTD)0.25%
Gross Margin (TTM)75.69%
Net Profit Margin (TTM)13.07%
EPS (TTM)$8.81
10-Day Avg Trading Volume1.34M
EPS Excl Extra (TTM)$8.81
Revenue Growth (5Y)-5.96%
EPS (Annual)$8.79
ROI (Annual)5.27%
Gross Margin (Annual)75.99%
Net Profit Margin (5Y Avg)17.17%
Cash / Share (Quarterly)$26.01
P/E Basic Excl Extra (TTM)20.84x
Revenue Growth QoQ (YoY)-7.14%
EPS Growth (5Y)-18.77%
P/E Normalized (Annual)20.84x
ROA (Last FY)4.39%
Revenue Growth TTM (YoY)2.22%
EBITD / Share (TTM)$17.33
ROE (5Y Avg)12.34%
Operating Margin (TTM)17.42%
Cash Flow / Share (Annual)$13.76
P/B Ratio1.48x
P/B Ratio (Quarterly)1.41x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.06x
Net Interest Coverage (TTM)4.24x
ROA (TTM)4.50%
EV / EBITDA (TTM)11.88x
EPS Incl Extra (Annual)$8.79
Current Ratio (Annual)2.68x
Quick Ratio (Quarterly)2.03x
3-Month Avg Trading Volume1.55M
52-Week Price Return54.57%
EV / Free Cash Flow (Annual)14.97x
P/E Incl Extra (TTM)20.84x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$61.88
P/S Ratio (Annual)2.72x
Asset Turnover (Annual)0.34x
52-Week High$202.41
Operating Margin (5Y Avg)24.59%
EPS Excl Extra (Annual)$8.79
CapEx CAGR (5Y)-19.60%
Tangible BV CAGR (5Y)3.58%
26-Week Price Return26.71%
Quick Ratio (Annual)1.82x
13-Week Price Return8.76%
Total Debt / Equity (Annual)0.34x
Current Ratio (Quarterly)2.68x
Enterprise Value$30,220.232
Revenue / Share Growth (5Y)-4.24%
Asset Turnover (TTM)0.34x
Book Value / Share Growth (5Y)12.07%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.03x
Pretax Margin (Annual)15.74%
Cash / Share (Annual)$26.01
3-Month Return Std Dev35.42%
Gross Margin (5Y Avg)77.42%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-12.78%
ROE (Last FY)7.08%
Net Interest Coverage (Annual)4.24x
EPS Basic Excl Extra (Annual)$8.79
P/FCF (TTM)13.34x
Receivables Turnover (TTM)5.29x
EV / Free Cash Flow (TTM)14.97x
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$8.81
Receivables Turnover (Annual)5.29x
ROI (TTM)5.37%
P/S Ratio (TTM)2.72x
Pretax Margin (5Y Avg)19.96%
Revenue / Share (Annual)$67.24
Tangible BV / Share (Annual)$61.88
Forward P/E12.09x
Free OCF CAGR (5Y)-11.30%
Price vs S&P 500 (52W)19.94%
P/E Ratio (TTM)20.84x
EPS Growth TTM (YoY)-21.30%
Year-to-Date Return4.18%
5-Day Price Return2.45%
EPS Normalized (Annual)$8.79
ROA (5Y Avg)6.69%
Net Profit Margin (Annual)13.07%
Month-to-Date Return0.01%
Cash Flow / Share (TTM)$13.34
EBITD / Share (Annual)$17.30
EPS Growth (3Y)-25.04%
Operating Margin (Annual)17.42%
LT Debt / Equity (Annual)0.34x
P/CF (TTM)12.22x
ROI (5Y Avg)8.35%
P/E Excl Extra (TTM)20.84x
LT Debt / Equity (Quarterly)0.34x
EPS Basic Excl Extra (TTM)$8.81
P/TBV (Quarterly)2.84x
P/B Ratio (Annual)1.41x
Inventory Turnover (TTM)1.04x
Pretax Margin (TTM)15.74%
Book Value / Share (Annual)$124.45
Price vs S&P 500 (13W)6.38%
Net Margin Growth (5Y)-15.17%
Beta0.16x
P/FCF (Annual)13.34x
Revenue / Share (TTM)$67.37
ROE (TTM)7.28%
52-Week Low$114.66
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.67
3.67
3.65
3.65
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
HALOHalozyme Therapeutics, Inc. | 5.90x | 37.55% | 83.62% | 22.89% | $69.57 |
About
Biogen is a biopharmaceutical company focused on neurodegenerative and rare diseases. Its revenue base is anchored by multiple sclerosis therapies (40% of 2025 revenue) and a CD20 collaboration with Roche (19%), though the MS franchise is declining. The company is diversifying through emerging treatments including Leqembi for Alzheimer's disease, Spinraza for spinal muscular atrophy, and programs addressing postpartum depression, Friedreich's ataxia, and amyotrophic lateral sclerosis.